
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort is a trusted and leading provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a strong focus on supporting the rapidly growing cell and gene therapy market. The company has a proven track record of strong revenue growth, with both of its segments – Life Sciences Services and Life Sciences Products – experiencing double-digit growth in the latest quarter. Additionally, CryoPort has a strong pipeline of potential future approvals for its key customers. While there are some risks in the market and potential for competition, CryoPort's strong financial performance and expanding market share make it an attractive investment option for those looking to capitalize on the growth of the cell and gene therapy industry.
Bears say
CryoPort is experiencing strong revenue growth and is expected to see further growth in the future, but risk factors such as potential supply chain disruptions, regulatory challenges, and competition in a highly competitive and heavily regulated industry could negatively impact their financial performance. Additionally, their reliance on third parties for key software and shipping services exposes them to potential delays or failures in product delivery. These risks, combined with a current valuation at a premium compared to their small/mid-cap peers, lead to a negative outlook on CYRX stock.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares